Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31395484 | 0.83 | DHODH (0.58) | DHODHMEN1KMT2AMAPTGRM4 | |
| SCHEMBL23319512 | 0.79 | ABCG2 (0.50) | DHODHMEN1KMT2AALDH1A1ABCG2 | |
| SCHEMBL30114249 | 0.79 | EPHX2 (0.56) | DHODHMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL30519327 | 0.79 | PIP4K2A (0.44) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL25339954 | 0.79 | PIP4K2A (0.44) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL24879902 | 0.79 | EPHX2 (0.56) | DHODHMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL2037022 | 0.78 | DHODH (0.57) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6689566 | 0.78 | DHODH (0.58) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4721393 | 0.78 | DHODH (0.58) | DHODHMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL20385251 | 0.76 | DHODH (0.56) | DHODHMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943480-B1 | PIPERIDINYLCARBAZOLE AS ANTIMALARIAL | MERCK PATENT GMBH (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-9908863-B2 | Piperidinylcarbazoles | MERCK PATENT GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-9908863-B2 | Piperidinylcarbazoles | MERCK PATENT GMBH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014108168-A1 | PIPERIDINYLCARBAZOLE AS ANTIMALARIAL | MERCK PATENT GMBH (DE) | 2014-07-17 | — | — | WO | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
| US-8513270-B2 | Substituted heterocycles as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-08-20 | — | — | US | disclosed |
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| CN-1197860-C | FAB I inhibitors | SMITHKLINE BEECHAM CORP (CA) | 2005-04-20 | — | — | CN | disclosed |
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| CN-1378542-A | Antigen binding fragment I inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | CN | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | DHODH 1581/4885MEN1 3468/4885KMT2A 4427/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | DHODH 1581/4885MEN1 3468/4885KMT2A 4427/4885 |
| US-20150368226-A1 | PIPERIDINYLCARBAZOLES | PSEN1, ARG2, UQCRC1 | DHODH 2345/4885MEN1 2490/4885KMT2A 2265/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | DHODH 658/4885MEN1 1627/4885KMT2A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.